Arthrosi Therapeutics, Inc, a pharmaceutical company founded in 2018 by a team of well-established experts in drug development, announced the first blockbuster-potential molecule, AR882, to treat gout.

GenScript, the world's leading reagents provider, announced today the launch of its Research Lentiviral Vector Packaging Service for cell line development, gene editing, and drug discovery.

GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), Parkway Laboratories and the Diagnostics Development (DxD) Hub announced their collaboration to provide the cPass™ SARS-CoV-2 neutralizing antibody test in Singapore through Parkway’s panel of specialist and GP clinics.

At this year’s Spring Banquet held on April 6th, the Board of directors, major shareholders, and the senior management team of EirGenix, Inc (6589.TT) were witness to a monumental event.

Advaxis, Inc. announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021.

Advaxis, Inc. announced that the Company has received the second milestone payment related to its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans.

 Advaxis, Inc. (Nasdaq: ADXS) announced data on the development of a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic marker during PD-1 blockade, and translational data demonstrating immune responses correlated to observed clinical benefit from the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA^®

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an agreement with Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer.

Taipei, Taiwan, March 28, 2021 – Foresee Pharmaceuticals Co., Ltd. (6576.TWO) (“Foresee”), today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome (ARDS).

N/A